Cladribine reduced T- and B-cell proliferation in PHA-stimulated PBMC cultures, while NK-cell proliferation was unaffected. A separate 16-hour experiment detected increased early apoptosis in T, B and NK populations. [1]
In cultured lymphocytes from eight MS patients and four controls, 5 nM cladribine for four days produced no detectable increase in mitochondrial DNA mutations. This exploratory result is limited to the tested exposure and assay sensitivity; it does not exclude other mitochondrial effects. [2]
Deoxycytidine rescue of PBMC proliferation
Cell-based study · Human PBMCs from healthy donors and relapsing-remitting MS patients; PHA-stimulated subsets; N = 10 reported for Figure 2. [1]
Cladribine impaired proliferation of T and B cells, but not NK cells; excess deoxycytidine prevented the inhibitory response.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.1 or 1 μM cladribine; rescue conditions contained 250 μM deoxycytidine.
- Exposure duration
- PHA 0.25 μg/mL for 96 h; cladribine during the last 48 h; deoxycytidine pretreatment 30 min.
- Method
- CFSE dilution by flow cytometry; no-cladribine and deoxycytidine-only comparators; repeated-measures ANOVA with Dunnett comparisons.
- Vehicle
- Cladribine dissolved in DMSO, then diluted in complete medium.
- Co-treatment
- Deoxycytidine used as a competing DCK substrate; PHA supplied the proliferative stimulus.
- Reported limits
- Final DMSO percentage and explicit solvent matching are not stated in the read methods. Supplementary Figure S1 gating image not retrieved.
Methods and source locations
Compound reported in the paper: Cladribine; Compound label in the paper: 2-chlorodeoxyadenosine
Named cladribine in the reported culture system; supplier lot equivalence and clinical efficacy are not established.
Methods 2.3, 2.4.1, 2.6–2.7; Results 3.2; Figure 2 and caption (PDF p.6)
Percentage of cells with diluted CFSE: CFSE dilution by flow cytometry; no-cladribine and deoxycytidine-only comparators; repeated-measures ANOVA with Dunnett comparisons. — Methods 2.3, 2.4.1, 2.6–2.7; Results 3.2; Figure 2 and caption (PDF p.6)
Deoxycytidine rescue of early PBMC apoptosis
Cell-based study · Human PBMCs from healthy donors and relapsing-remitting MS patients; PHA-stimulated subsets; N = 10 reported for Figure 3. [1]
Cladribine increased early apoptosis in T, B and NK populations; deoxycytidine prevented this response.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.1 or 1 μM cladribine; rescue conditions contained 250 μM deoxycytidine.
- Exposure duration
- 16 h with PHA 5 μg/mL; deoxycytidine pretreatment 30 min.
- Method
- Annexin V/7AAD flow cytometry; no-cladribine and deoxycytidine-only comparators; repeated-measures ANOVA with Dunnett comparisons.
- Vehicle
- Cladribine dissolved in DMSO, then diluted in complete medium.
- Co-treatment
- Deoxycytidine rescue; PHA stimulation.
- Reported limits
- Final DMSO percentage and explicit solvent matching not stated in the read methods. Supplementary Figure S2 gating image not retrieved.
Methods and source locations
Compound reported in the paper: Cladribine; Compound label in the paper: 2-chlorodeoxyadenosine
Named cladribine in the reported culture system; supplier lot equivalence and clinical efficacy are not established.
Methods 2.3, 2.4.2, 2.6–2.7; Results 3.3; Figure 3 and caption (PDF p.6)
Annexin V-positive, 7AAD-negative cells: Annexin V/7AAD flow cytometry; no-cladribine and deoxycytidine-only comparators; repeated-measures ANOVA with Dunnett comparisons. — Methods 2.3, 2.4.2, 2.6–2.7; Results 3.3; Figure 3 and caption (PDF p.6)
Mitochondrial DNA mutations after low-dose exposure
Cell-based study · PBMC cultures from eight relapsing MS patients and four healthy controls; CD4+, CD8+ and CD19+ populations separated after treatment. [2]
No detectable treatment-associated increase in mitochondrial DNA mutations was found in these cultured lymphocyte populations.
Literature-Reported Treatment Conditions
- Treatment concentration
- 5 nM cladribine
- Exposure duration
- 4 days after 1 day of conditioning.
- Method
- Next-generation mtDNA amplicon sequencing; untreated parallel cultures; Wilcoxon rank sum tests for Figure 5a,c and Student t-test for Figure 5b.
- Vehicle
- Not specified in the read original text.
- Co-treatment
- No other drug treatment reported for this experiment.
- Reported limits
- Supplier, lot, stock solvent and analytical form characterization are not specified in the retrieved original methods.
Methods and source locations
Compound reported in the paper: Cladribine; Compound label in the paper: 2-chlorodeoxyadenosine
Named cladribine in the reported culture system; supplier lot equivalence and clinical efficacy are not established.
Methods: Ex vivo sample collection, PBMC cultures, cell separation, next-generation sequencing, somatic mutation calling and Statistical analysis; Results: Somatic mutations in mtDNA in human cultured ex vivo lymphocytes; Figure 5 (advance-access PDF p.7; retained PDF page 8)
Mitochondrial DNA mutation rates and distribution: Next-generation mtDNA amplicon sequencing; untreated parallel cultures; Wilcoxon rank sum tests for Figure 5a,c and Student t-test for Figure 5b. — Methods: Ex vivo sample collection, PBMC cultures, cell separation, next-generation sequencing, somatic mutation calling and Statistical analysis; Results: Somatic mutations in mtDNA in human cultured ex vivo lymphocytes; Figure 5 (advance-access PDF p.7; retained PDF page 8)